title: Therapeutic dendritic-cell vaccine for simian AIDS.
abstract: An effective immune response against human immunodeficiency virus or simian immunodeficiency virus (SIV) is critical in achieving control of viral replication. Here, we show in SIV-infected rhesus monkeys that an effective and durable SIV-specific cellular and humoral immunity is elicited by a vaccination with chemically inactivated SIV-pulsed dendritic cells. After three immunizations made at two-week intervals, the animals exhibited a 50-fold decrease of SIV DNA and a 1,000-fold decrease of SIV RNA in peripheral blood. Such reduced viral load levels were maintained over the remaining 34 weeks of the study. Molecular and cellular analyses of axillary and inguinal node lymphocytes of vaccinated monkeys revealed a correlation between decreased SIV DNA and RNA levels and increased SIV-specific T-cell responses. Neutralizing antibody responses were augmented and remained elevated. Inactivated whole virus-pulsed dendritic cell vaccines are promising means to control diseases caused by immuno- deficiency viruses.
authors.affiliation: Institut de Recherche sur les Vaccins et l'Immunothérapie des Cancers et du Sida, Paris, France. louis.wei-lu@biomedicale.univ-paris5.fr
authors.forename: Wei
authors.initials: W
authors.lastname: Lu
authors.forename: Xiaoxian
authors.initials: X
authors.lastname: Wu
authors.forename: Yaozeng
authors.initials: Y
authors.lastname: Lu
authors.forename: Weizhong
authors.initials: W
authors.lastname: Guo
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Andrieu
mesh_terms: D015082:2,2'-Dipyridyl / Q000031:analogs & derivatives* / Q000378:metabolism; D016915:AIDS Vaccines / Q000276:immunology / Q000627:therapeutic use; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D004220:Disulfides / Q000378:metabolism; D005260:Female; D015658:HIV Infections / Q000276:immunology / Q000628:therapy; D006801:Humans; D007111:Immunity, Cellular; D008198:Lymph Nodes / Q000276:immunology / Q000473:pathology / Q000821:virology; D008253:Macaca mulatta; D008297:Male; D009500:Neutralization Tests; D016877:Oxidants / Q000378:metabolism; D012367:RNA, Viral / Q000032:analysis; D018449:SAIDS Vaccines / Q000276:immunology / Q000627:therapeutic use*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000628:therapy*; D015302:Simian Immunodeficiency Virus / Q000276:immunology* / Q000502:physiology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination; D019562:Viral Load
chemical_list: D016915:AIDS Vaccines; D000914:Antibodies, Viral; D004220:Disulfides; D016877:Oxidants; D012367:RNA, Viral; D018449:SAIDS Vaccines; C001105:2,2'-dipyridyl disulfide; D015082:2,2'-Dipyridyl